Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06102005 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 685
- Enrollment target
NCT06102005 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 685 participants.
The verdict
NCT06102005, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 685 participants
- Enrollment target
Study Summary
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Interventions
- DRUG Placebo
- DRUG Lunsekimig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2026-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06102005
The ClinicalTrials.gov registry entry for NCT06102005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 685 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06102005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06102005 about?
NCT06102005 is a clinical study titled "Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma". This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
What is the current status of trial NCT06102005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 685 participants. The study started on 2023-10-16. Estimated completion is 2026-03-11.
What interventions are being tested in trial NCT06102005?
The interventions under investigation include: Placebo (DRUG), Lunsekimig (DRUG).
Who is sponsoring clinical trial NCT06102005?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.